FindTrial
Sign In

Port Delivery System with Ranibizumab

COMBINATION_PRODUCT2 trials

Sponsors

Hoffmann-La Roche

Conditions

Branch Retinal Vein OcclusionCentral Retinal Vein OcclusionDiabetic Macular EdemaHemi-retinal Vein OcclusionNeovascular Age-related Macular DegenerationNeovascular Age-related Macular Degeneration (nAMD)Retinal Vein Occlusion

Phase 3

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Active, not recruitingNCT04657289
Hoffmann-La RocheNeovascular Age-related Macular Degeneration (nAMD)
Start: 2021-07-14End: 2027-02-04Updated: 2026-07-31

Unknown Phase

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Active, not recruitingNCT05476926
Hoffmann-La RocheBranch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diabetic Macular Edema +3
Start: 2022-11-21End: 2027-11-30Target: 6000Updated: 2026-09-02

Related Papers

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
2024-07-319 citations
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial.
2024-03-143 citations
Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice.
2023-12-033 citations